Tin tức & Cập nhật
Xem bài viết Multidisciplinary
Xem
Chỉ hiển thị Multimedia

SC dose escalation restores efficacy of infliximab in IBD patients
17 Feb 2025
bởiStephen Padilla
Escalating the dose of subcutaneous (SC) CT-P13, a biosimilar of infliximab, from 120 to 240 mg every 2 weeks appears to bring back the efficacy of the drug in patients with inflammatory bowel disease (IBD) who no longer respond to treatment, suggests a study presented at 2025 Crohn's & Colitis Congress.








